行情

CRIS

CRIS

居里
NASDAQ

实时行情|Nasdaq Last Sale

1.280
+0.020
+1.59%
交易中 13:21 08/14 EDT
开盘
1.260
昨收
1.260
最高
1.290
最低
1.240
成交量
37.19万
成交额
--
52周最高
3.590
52周最低
0.6200
市值
6,895.09万
市盈率(TTM)
-1.4150
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CRIS价格均价为9.00,最高价位9.00,最低价为9.00。

EPS

CRIS 新闻

更多
Curis EPS beats by $0.03, misses on revenue
Curis (NASDAQ:CRIS): Q2 GAAP EPS of -$0.17 beats by $0.03. Revenue of $2.36M (+12.9% Y/Y) misses by $0.34M. Shares +1.5%. Press Release
seekingalpha · 08/05 01:03
Curis Q2 EPS $(0.17) Beats $(0.18) Estimate, Sales $2.36M Miss $2.55M Estimate
Curis (NASDAQ:CRIS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 22.73 percent increase over losses of $(0.22) per share from the same
Benzinga · 08/04 20:14
Curis Reports Second Quarter 2020 Financial Results
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2020.
PR Newswire · 08/04 20:01
3 “Strong Buy” Penny Stocks That Could Go Boom
The stock market has been holding up remarkably well, but why? Against the backdrop of weak second quarter earnings results, investors are piling in on the hope that a COVID-19 vaccine is coming, there will be additional stimulus and corporate profits will bou
TipRanks · 08/04 19:31
Curis to Release Second Quarter 2020 Financial Results and Hold Conference Call on August 4, 2020
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2020 financial results on Tuesday, August 4, 2020, after the
PR Newswire · 07/28 12:00
Curis Doses First Patient In Phase 1 Study of CA-4948 In Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes
Benzinga · 07/07 12:14
Curis Doses First Patient in Phase 1 Study of CA-4948 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in its Phase 1 trial evaluating CA-4948, a novel, small molecule IRAK4
PR Newswire · 07/07 12:00
Curis Shares Move Higher After Jones Trading Initiates Coverage With Buy Rating, Sets $5 Price Target
-Reuters
Reuters · 06/23 12:23

所属板块

生物技术和医学研究
-0.70%
制药与医学研究
-0.32%

热门股票

代码
价格
涨跌幅

CRIS 简况

Curis, Inc.是一家生物技术公司。该公司从事治疗人类癌症的候选药物的开发及商业化业务。该公司的候选药物CUDC-907是一种口服的脱乙酰化酶(HDAC)及磷脂酰肌醇-3-激酶(PI3K)的小分子抑制剂。该公司开发多种产品。CA-170是口服的小分子候选药物。CA-4948是一种用于抑制白细胞介素1受体相关激酶4(IRAK4)的口服小分子候选药品。Erivedge是口服的小分子生物制药,被用于选择性地抑制刺猬信号通路。CUDC-427是一种通过对抗细胞凋亡抑制(IAP)蛋白促进癌细胞死亡的口服小分子胱天蛋白酶激活剂(Smac)类似物。CUDC-305是一种用于治疗晚期肺癌的口服热休克蛋白90(HSP90)抑制剂。
展开

微牛提供Curis, Inc.(NASDAQ-CRIS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CRIS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CRIS股票基本功能。